{
  "docId": "019de516-48a5-7631-970d-a6192a59c040",
  "docSlug": "5b4cac48a3342d745accb48141e027b4",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 39 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 39,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 48,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de516-48a5-7631-970d-a6192a59c040/10",
  "deckHref": "/decks/019de516-48a5-7631-970d-a6192a59c040",
  "deckJsonHref": "/decks/019de516-48a5-7631-970d-a6192a59c040.json",
  "deckAnchorHref": "/decks/019de516-48a5-7631-970d-a6192a59c040#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.16,
        "w": 0.239,
        "x": 0.71,
        "y": 0.235
      },
      "kind": "list",
      "text": "2Q23 FX Headwinds:\n-$18M Revenue\n-$25M Adj. EBITDA",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70edc374-d4c8-472a-ac62-a77bf1934349",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.275,
        "w": 0.249,
        "x": 0.71,
        "y": 0.479
      },
      "kind": "list",
      "text": "Year-Over-Year Comparability\n2Q23 results include stand-alone costs associated with the Bausch + Lomb separation\n2Q22 results are not fully burdened by stand-alone costs",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7846c9f5-a825-4c77-9ff6-98d962b2f9ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.066,
        "w": 0.742,
        "x": 0.154,
        "y": 0.913
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.\n3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.\n4. 2Q22 results were not fully burdened by all stand-up costs associated with the separation.\n5. Includes transactional FX and NCI. Currency headwind (translational and transactional) was ~$25M to Adj. EBITDA for 2Q23. The 2Q22 transactional FX impact was a gain of $14M.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e03f39d4-ca06-4799-84de-4b1eb7fd09c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.739,
        "w": 0.65,
        "x": 0.046,
        "y": 0.153
      },
      "kind": "table",
      "text": "Bausch + Lomb\nVision Care Revenue3\nSurgical Revenue\nPharmaceuticals Revenue3\nTotal Revenue\nAdj. Gross Profit2\nAdj. Gross Margin²\nR&D\nR&D % of Revenue\nAdj. SG&A2\nAdj. SG&A % of Revenue\nAdj. EBITA2\nDepreciation\nStock Based Compensation\nAdj. EBITDA2,5\nAdj. EBITDA Margin²\nAdj. Net Income Attributable to Bausch + Lomb²\nAdj. EPS Attributable to Bausch + Lomb²",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74741144-6ea3-41f5-a9a6-a9480ca929a3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "c5860bd7-2ab7-4c76-85b4-b8c331353e31",
      "evidence": "Bausch + Lomb Vision Care Revenue3 Surgical Revenue Pharmaceuticals Revenue3 Total Revenue Adj. Gross Profit2 Adj. Gross Margin² R&D R&D % of Revenue Adj. SG&A2 Adj. SG&A % of Revenue Adj. EBITA2 Depreciation",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 9,
      "beatId": "9630bb99-f6be-4279-92e2-bb79342bf55e",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Bausch + Lomb showcases its financial performance and progress.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}